Viiv Healthcare UK (no.5) Limited

Bristol-myers Squibb Compnay

Bayer Healthcare LLC

Bayer Intellectual Property Gmbh

Viiv Healthcare UK Limited

Manoj Patel

B Narasimhulu Naidu

Kevin M Peese

John F Kadow

Michael A Walker

Zhongyu Wang

Margaret E Sorenson

Timothy P Connolly

Zhizhen Barbara Zheng

Stanley V D'Andrea

Chen Li

Tao Wang

Zhongxing Zhang

Makonen Belema

David R Langley

Kyle E Parcella

Nicholas A Meanwell

John A Bender

Mark George Saulnier

Zhiwei Yin

Eric P Gillis

Prasanna Sivaprakasam

Alan Xiangdong Wang

Ramkumar Rajamani

Michael S Bowsher

Julie A Dixon

Barry L Johnson

Christiana Iwuagwu

Ellalahewage Sathyajith Kumarasinghe

Philip Wickens

Brian Richard Bear

Dhanapalan Nagarathnam

Annapurna Pendri

Barton W Phillips

Steven R Magnuson

Alexander Hillisch

Jeffrey Lee Romine

Denis R St Laurent

Yasutsugu Ueda

Karl-Heinz Thierauch

Hartmut Beck

David Bertil Frennesson

Samuel Gerritz

Uday R Khire

Kyle J Eastman

Martin F Hentemann

Zhonghua Zhang

Yong Tu

Yuanwei Chen

Martin D Eastgate

Francis Beaulieu

Michael Härter

Holger Hess-Stumpp

Ming Wang

Bin Zheng

Philip L Wickens

Guo Li

Carl Ouellet

Ke Chen

Pulicharla Nagalakshmi

Susanne Greschat

Selvakumar Kumaravel

Jianqing Chen

Weixu Zhai

Ann-Marie Bullion

Chunguang Wang

Michael Brands

Lin Yi

Donald Bierer

Francisco Gonzalez-Bobes

Peter Ellinghaus

Ira B Dicker

Lei Wang

Wenlang Fu

Stephen James Boyer

Alan Olague

Lei Zhang

Rongti Li

Jonathan R Weiss

Yasutsuga Ueda

Ajay Kumar Bhargava

Suresh Babu

Patrick Paulus

Julie Dixon

Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:

Inhibitors of human immunodeficiency virus replication

Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: 

4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication

Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth. 

Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS. 

Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV. 

Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication

The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection. 

Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication

Benzothiazole macrocycles as inhibitors of human immunodeficiency virus replication

Imidazopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication

The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV integrase, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection. 

The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection. Formule (I). 

The disclosure generally relates to compounds of formula (I), including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection. 

Growing community of inventors

Berlin, CT, United States of America

Manoj Patel